MARKET ACCESS SERVICES
Value propositions and value dossiers (VPVD) enable pharmaceutical industry to demonstrate the comparative advantage of their products over the recognised standard therapies to HTA organisations as to realise successful market access of their products.
Value propositions and value dossiers are prepared through a comprehensive synthesis of supporting evidence on the clinical, economic and humanistic value for the new intervention. The VPVD are constructed with the aim to provide a meaningful value proposition, with clear and concise messages for dissemination to the relevant departments (sale, marketing and market access) as well as health authorities and medical society.
The reimbursement dossiers are part of the value dossiers and are constructed by taking into account the national or regional requirements of the HTA bodies. The product benefits (innovative, therapeutic, and quality of life) are demonstrated through cutting edge analytical tools such as economic modelling and clinical trials. The reimbursement dossiers aim at positioning the product in a strategic manner for an HTA submission.
Pharmecons can support you during the reimbursement price negotiation with the Greek Pharmaceuticals Negotiation Committee. We can help you through various steps of the process such as:
- the preparation of the necessary argumentation in order to support your value proposition
- Set up of mock-up negotiations to prepare the composition, structuring, roles and coordination of your negotiation team
- In-person presence during the Negotiation meeting
Our experience in pricing and reimbursement systems of many European countries and several disease areas enables us to provide strategic guidance for your product and prepare a plan for a successful negotiation.
HEALTH ECONOMICS & OUTCOMES RESEARCH SERVICES
Economic modelling is a focal point of the economic evaluation of a new health technology, since it supports the decision making by bringing together the evidence on costs, outcomes and epidemiological data. Economic models can take the nature of a global health technology assessment (HTA) tool, which is built for reimbursement purposes, or simpler, but equally useful early-models to assist with business development scenarios. Our team has extensive experience in economic modelling (cost-effectiveness, budget impact models) in a number of disease areas and undertakes de novo model building as well as adaptation of global models for use in the local markets.
ALONGSIDE CLINICAL TRIALS
Outcomes research enables capturing the value of healthcare interventions and services. The experience and preferences of patients for health care interventions, as well as clinical outcomes, including patient reported outcomes (PROs) is a focal point of this strand of research.
Our outcomes research tools include a variety of analytical approaches such as utility elicitation, discrete choice experiments and PROs.
Eliciting patients’ preferences has been deemed as an important step when assessing the value of a new health care technology. Placing the patient in the centre of the decision making process for their own health and treatment options, is increasingly being demanded from the reimbursement authorities. Equally, preferences of payers and commissioners are taken into account.
The DCEs and BWS are two of the preferred methods for preference elicitation. We are in position to design DCEs & BWS assemble the appropriate team for conducting the qualitative work, collect and analyse data, providing your organization with a complete package of service around preference elicitation.
Through the use of appropriate methods, we can generate utility values for different disease areas. Utility values are elicited over a period of time for individual patients. This enables the calculations of quality adjusted life years (QALYs) which is used as an outcome measure in economic evaluation.
The battery of methods include standard gamble (SG) or time-trade off (TTO) techniques for direct elicitation of utility values or off-the shelf, generic questionnaires (such as EQ-5D) for the indirect elicitation. We have great experience in conducting utility elicitation and data analysis with the use of all the suggested methods.
Patient-reported outcomes (PROs) have been defined as “any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else.” A wide variety of PROs tools have been developed and used in clinical practice. PROs are often recorded in clinical trials, using validated instruments (PROMs) to measure the impact of the intervention as perceived by the patient.
Our team can guide you, via an evidence-based approach, through the choice of the appropriate PRO tools for use in clinical trials or general policy decisions.
& OUTCOMES RESEARCH
Patient experiences have become a key quality indicator for healthcare. Measuring and analyzing experiences is considered a tool to support improvement in healthcare quality governance, public accountability, and patient choice. Pharmecons has experience in patient satisfaction studies, patient journey research and patient-perceived disease burden experience. The elicitation methods we use are adaptable to each specific objective and research nature. They might involve position papers, advisory boards with patient advocates, social media analysis & gathering, focus groups and systematic literature review. Each method used is specially designed to meet the specific objective and satisfy client’s need, leading to successful reimbursement.